Drug Profile
Oremepermin alfa - Kringle Pharma
Alternative Names: Hepatocyte growth factor - Kringle Pharma; KP-100 - Kringle Pharma; KP-100IT; KP-100LILatest Information Update: 13 Dec 2022
Price :
$50
*
At a glance
- Originator Kringle Pharma
- Class Antifibrotics; Growth factors; Neuropsychotherapeutics
- Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cell death inhibitors; Proto-oncogene protein c-met modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Scars; Spinal cord injuries
- Phase II Amyotrophic lateral sclerosis
- No development reported Acute kidney injury